May 14, 2020
SciMount announces FDA approval of SMP-100's IND application for the treatment of Irritable Bowel Syndrome
Mar 09, 2020
The irritable bowel syndrome treatment market was valued at $1,071 million in 2018, and is estimated to reach at $2,012 million by 2026, registering a CAGR of 8.2% from 2019 to 2026
Dec 10, 2019
Slayback Pharma announces approval and immediate launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in 200 mcg/ 50 mL and 400 mcg/ 100 mL (4 mcg/mL) vials, generic equivalent of Precedex(TM) 4 mcg/ mL
Sep 04, 2018
Genoptix Launches FDA-Authorized BCR-ABL MRDx® TFR Monitoring Test for Patients with Chronic Myeloid Leukemia on Tasigna®(nilotinib)
Jun 06, 2018
Daiichi Sankyo's U.S. Products Liability Litigation Settlement Program Moves Forward; More than 97 Percent of Eligible Litigants and Claimants Opt In
Jun 02, 2018
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy
Mar 22, 2018
Novartis drug Tasigna® approved by FDA to treat children with rare form of leukemia
Feb 23, 2018
Amgen Receives Positive Opinion Expanding Use Of XGEVA® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Aug 22, 2017
Teikoku Pharma USA Announces Positive Topline Results from Phase 2 Clinical Trial of TPU-006, Non-Opioid Pain Management Patch in Bunionectomy Surgery
Aug 01, 2017
Daiichi Sankyo Announces Settlement Agreement on U.S. Products Liability Litigation
Jun 19, 2017
FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA® (denosumab) To Include Multiple Myeloma Patients
Jun 04, 2017
Amgen Presents New Data From Phase 3 XGEVA® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017